DPP4 and Hypoglycemia: DPP-4 inhibitors act by increasing active glucagon-like peptide-1 (GLP-1) in blood through inhibition of DPP-4, which stimulates glucose-dependent insulin secretion and inhibits glucagon secretion, leading to reduced glucose levels with a low incidence of hypoglycemia [8].